linagliptin and semaglutide together Is it safe to combine (a DPP‑4 inhibitor) with (a GLP‑1 receptor agonist) in a patient with type 2 diabetes who is already taking empagliflozin (an SGLT2 inhibitor)? Targeting GLP-1, GIP & GCG

The 7.2 mg dose was approved to help patients achieve deeper weight reductionproducing nearly 20% total weight loss in the STEP UP clinical trialsputting its efficacy much closer to that of tirzepatide

When you can't increase your dose further, your options become limited within the Wegovy framework

Rare but possible: headaches, dizziness, and injection site reactions

The intensity depends on your starting dose, individual metabolism, and genetic sensitivity to GLP-1 signaling

Lose up to 15% of your body weight with professional medical support for safe, effective, and sustainable results

People without diabetes have fluctuating insulin levels throughout the day